Biofourmis and Yale-Mayo CERSI to Study Heart Failure Patients

Biofourmis has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation. Biofourmis' BiovitalsHF will be used in a study, beginning in August 2019, of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.

To learn more about the upcoming study, click here.